ENLV
ENLV
NASDAQ · Biotechnology

Enlivex Therapeutics Ltd

$1.16
+0.00 (+0.00%)
As of Feb 8, 2:00 PM ET ·
Income Statement
FY 2025 FY 2024 FY 2023
Revenue 40.60M 42.46M 39.37M
Net Income -1,409,045 -1,565,662 -1,719,749
EPS
Profit Margin -3.5% -3.7% -4.4%
Rev Growth +15.5% -1.3% +12.3%
Balance Sheet
FY 2025 FY 2024 FY 2023
Total Debt 99.49M 133.12M 107.62M
Total Equity 207.23M 172.35M 188.36M
D/E Ratio 0.48 0.77 0.57
Cash Flow
FY 2025 FY 2024 FY 2023
EBITDA -2,559,719 -2,552,246 -2,827,370
Free Cash Flow -1,137,405 -963,691 -1,418,550